Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients | Zendy

Éric Deutsch | Zendy; Christine Haie-Méder | Zendy; Mohamed Amine Bayar | Zendy; Michele Mondini | Zendy; Mélanie Laporte | Zendy; R. Mazeron | Zendy; Julien Adam | Zendy; Andréa Varga | Zendy; Gilles Vassal | Zendy; Nicolas Magné | Zendy; Cyrus Chargari | Zendy; Émilie Lanoy | Zendy; Patricia Pautier | Zendy; Antonin Lévy | Zendy; JeanCharles Soria | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients

Author(s) -

Éric Deutsch,

Christine Haie-Méder,

Mohamed Amine Bayar,

Michele Mondini,

Mélanie Laporte,

R. Mazeron,

Julien Adam,

Andréa Varga,

Gilles Vassal,

Nicolas Magné,

Cyrus Chargari,

Émilie Lanoy,

Patricia Pautier,

Antonin Lévy,

JeanCharles Soria

Publication year - 2016

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.8224

Subject(s) - medicine , cidofovir , cervical cancer , neutropenia , population , adverse effect , gastroenterology , oncology , cancer , urology , surgery , toxicity , immunology , virus , environmental health

This phase I trial aimed to assess the safety and determine the recommended Phase II dose (RP2D) of Cidofovir combined with chemoradiotherapy in patients with stage IB2-IVA cervical cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research